SCHEMBL10954445

SCHEMBL10954445

COC(=O)CNC(=O)[C@@H](N)CC(C)C

nearest known ligand 0.45

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
SLC7A5 Q01650 1/20 0.45
TET2 Q6N021 1/20 0.42
ANPEP P15144 3/20 0.42
RNPEP Q9H4A4 2/20 0.42
DNPEP Q9ULA0 2/20 0.42
RECQL P46063 1/20 0.41
LARS1 Q9P2J5 1/20 0.40
SCN9A Q15858 3/20 0.39
TSHR P16473 1/20 0.39
HSD17B10 Q99714 1/20 0.39
AAK1 Q2M2I8 2/20 0.38
BIRC2 Q13490 1/20 0.38
SLC1A1 P43005 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10954441 1.00 SLC7A5 (0.45) SLC7A5TET2ANPEPRNPEPDNPEP
Hydrochloric Acid SCHEMBL10790535 0.98 SLC7A5 (0.44) SLC7A5TET2ANPEPRNPEPDNPEP
Hydrochloric Acid SCHEMBL3178894 0.98 SLC7A5 (0.44) SLC7A5TET2ANPEPRNPEPDNPEP
SCHEMBL8021280 0.84 GAA (0.45) SLC7A5ANPEPRNPEPDNPEPLARS1
SCHEMBL8021278 0.84 GAA (0.45) SLC7A5ANPEPRNPEPDNPEPLARS1
Hydrochloric Acid SCHEMBL9807062 0.83 GAA (0.44) SLC7A5ANPEPRNPEPDNPEPLARS1
Bromide SCHEMBL9807038 0.83 GAA (0.44) SLC7A5ANPEPRNPEPDNPEPLARS1
SCHEMBL24491202 0.81 SLC7A5 (0.48) SLC7A5ANPEPRNPEPDNPEPLARS1
SCHEMBL6047667 0.81 SLC7A5 (0.54) SLC7A5ANPEPRNPEPDNPEPLARS1
SCHEMBL5270305 0.81 SLC7A5 (0.48) SLC7A5ANPEPRNPEPDNPEPLARS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11572368-B2 Inhibitors of histone deacetylase THE GENERAL HOSPITAL CORPORATION (US) 2023-02-07 US disclosed
CN-110193086-B LA-GFLG-DOX conjugate and preparation method and application thereof 首都医科大学 2022-09-02 CN disclosed
US-11377423-B2 Inhibitors of histone deacetylase THE BROAD INSTITUTE, INC. (US) 2022-07-05 US disclosed
US-20210177781-A9 COMBINATION OF A SELECTIVE HISTONE DEACETYLASE 3 (HDAC3) INHIBITOR AND AN IMMUNOTHERAPY AGENT FOR THE TREATMENT OF CANCER KDAc Therapeutics, Inc. 2021-06-17 US disclosed
EP-2877444-B1 INHIBITORS OF HISTONE DEACETYLASE BROAD INST INC (US) 2020-09-02 EP disclosed
US-10662199-B2 Inhibitors of histone deacetylase THE BROAD INSTITUTE, INC. (US) 2020-05-26 US disclosed
US-10626438-B2 Fluorescent substrates for determining lysine modifying enzyme activity THE BROAD INSTITUTE, INC. (US) 2020-04-21 US disclosed
EP-2701699-B1 INHIBITORS OF HISTONE DEACETYLASE BROAD INST INC (US) 2019-10-16 EP disclosed
US-10421778-B2 Isoform-selective lysine deacetylase inhibitors WASHINGTON UNIVERSITY (US) 2019-09-24 US disclosed
US-20190216754-A1 COMBINATION OF A SELECTIVE HISTONE DEACETYLASE 3 (HDAC3) INHIBITOR AND AN IMMUNOTHERAPY AGENT FOR THE TREATMENT OF CANCER KDAC THERAPEUTICS INC (US) 2019-07-18 US disclosed
US-20150191427-A1 INHIBITORS OF HISTONE DEACETYLASE THE GENERAL HOSPITAL CORPORATION D/B/A MASSACHUSETTS GENERAL HOSPITAL (US) 2015-07-09 US disclosed
US-20140335550-A1 FLUORESCENT SUBSTRATES FOR DETERMINING LYSINE MODIFYING ENZYME ACTIVITY THE BROAD INSTITUTE, INC. (US) 2014-11-13 US disclosed
US-20140080802-A1 Inhibitors of Histone Deacetylase MASSACHUSETTS INSTITUTE OF TECHNOLOGY 2014-03-20 US disclosed
US-20140080800-A1 Inhibitors of Histone Deacetylase MASSACHUSETTS INSTITUTE OF TECHNOLOGY 2014-03-20 US disclosed
WO-2013067391-A1 FLUORESCENT SUBSTRATES FOR DETERMINING LYSINE MODIFYING ENZYME ACTIVITY THE BROAD INSTITUTE, INC. (US) 2013-05-10 WO disclosed
WO-2012149540-A1 INHIBITORS OF HISTONE DEACETYLASE THE BROAD INSTITUTE INC (US) 2012-11-01 WO disclosed
US-4555362-A Method and intermediates for producing α-L-aspartyl-L-phenylalanine G. D. SEARLE & CO. (US) 1985-11-26 US disclosed
EP-0130464-A1 Method and intermediates for producing alpha-L-aspartyl-L-phenylalanine G.D. Searle & Co. (US) 1985-01-09 EP disclosed
US-4480112-A ARTIFICIAL SWEETENER G. D. SEARLE & CO. (US) 1984-10-30 US disclosed
US-4440677-A N-ACETOACETYL-ALPHA-L-ASPARTYL-L -PHENYLALANINE METHYLESTER G. D. SEARLE & CO. (US) 1984-04-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140080800-A1 Inhibitors of Histone Deacetylase HDAC2, HDAC1, HDAC11 SLC7A5 3943/4885TET2 1024/4885ANPEP 4714/4885
US-20210177781-A9 COMBINATION OF A SELECTIVE HISTONE DEACETYLASE 3 (HDAC3) INHIBITOR AND AN IMMUNOTHERAPY AGENT FOR THE TREATMENT OF CANCER HDAC3, HDAC1, HDAC7 SLC7A5 4857/4885TET2 1131/4885ANPEP 2472/4885
US-10662199-B2 Inhibitors of histone deacetylase HDAC2, HDAC1, HDAC11 SLC7A5 3943/4885TET2 1024/4885ANPEP 4714/4885
US-11572368-B2 Inhibitors of histone deacetylase HDAC2, HDAC1, HDAC11 SLC7A5 3943/4885TET2 1024/4885ANPEP 4714/4885
US-20190216754-A1 COMBINATION OF A SELECTIVE HISTONE DEACETYLASE 3 (HDAC3) INHIBITOR AND AN IMMUNOTHERAPY AGENT FOR THE TREATMENT OF CANCER HDAC3, HDAC1, HDAC7 SLC7A5 4857/4885TET2 1131/4885ANPEP 2472/4885
US-20150191427-A1 INHIBITORS OF HISTONE DEACETYLASE HDAC3, HDAC1, HDAC5 SLC7A5 3259/4885TET2 3362/4885ANPEP 4132/4885
US-11377423-B2 Inhibitors of histone deacetylase HDAC3, HDAC1, HDAC11 SLC7A5 3638/4885TET2 3215/4885ANPEP 4135/4885
US-20140080802-A1 Inhibitors of Histone Deacetylase HDAC2, HDAC1, HDAC11 SLC7A5 3943/4885TET2 1024/4885ANPEP 4714/4885
US-10626438-B2 Fluorescent substrates for determining lysine modifying enzyme activity KDM1A, MAN2B1, KDM3A SLC7A5 3200/4885TET2 286/4885ANPEP 177/4885
US-10421778-B2 Isoform-selective lysine deacetylase inhibitors DOT1L, KDM1A, HDAC1 SLC7A5 3251/4885TET2 606/4885ANPEP 2933/4885
US-20140335550-A1 FLUORESCENT SUBSTRATES FOR DETERMINING LYSINE MODIFYING ENZYME ACTIVITY MAN2B1, KDM1A, KDM3A SLC7A5 3352/4885TET2 344/4885ANPEP 172/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.